Head and Neck Cancer News and Research

RSS

Head and Neck Cancer is cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx [voice box]).

Routine PET/CT scan use in head and neck cancer patients can detect local recurrences

Routine use of positron emission tomography/computed tomography (PET/CT) scans in head and neck cancer patient follow-up can detect local recurrences before they become clinically apparent and may improve the outcome of subsequent salvage therapy, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM.

27 Jan 2012

Boehringer Ingelheim initiates two afatinib phase III trials in head and neck cancer

Boehringer Ingelheim announced today the initiation of two phase III clinical trials, LUX-Head & Neck 1 and LUX-Head & Neck 2. These trials evaluate afatinib in patients with metastatic and recurrent head and neck cancer, and in patients with locally advanced disease, respectively.

27 Jan 2012

Multidisciplinary Head and Neck Cancer Symposium hosts research briefings

The Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM, will host two news briefings on top head and neck cancer research from its meeting January 26-28, 2012, in Phoenix.

24 Jan 2012

miR-375 can predict life threatening head and neck cancers

Researchers at Albert Einstein College of Medicine of Yeshiva University and Montefiore Medical Center, the University Hospital for Einstein, have found a biomarker in head and neck cancers that can predict whether a patient's tumor will be life threatening.

24 Jan 2012

Matted lymph nodes may predict throat cancer metastasis

Researchers at the University of Michigan Health System have found a new indicator that may predict which patients with a common type of throat cancer are most likely have the cancer spread to other parts of their bodies.

17 Jan 2012

OCF to offer free oral cancer screenings in April 2012

Did you know that the fastest growing segment of the oral cancer community is young, healthy non-smokers? It's shocking but true. Exposure to the HPV-16 virus, the most common sexually transmitted infection, is now the leading cause of oral cancers in the U.S. There is little that can be done to stop this virus from spreading. Our only hope to save lives is through increased professional involvement and public awareness to generate early discovery of the disease process.

7 Jan 2012

Free, low-cost strategies to maintain good health in the new year

With the start of a new year, Dana-Farber Cancer Institute experts are encouraging people to ring in new healthy habits and offer a number of free and low-cost strategies to help people maintain good health and possibly reduce various cancer risks.

29 Dec 2011

CEL-SCI to expand Multikine Phase III trial in head and neck cancer

CEL-SCI Corporation is in the process of expanding its Phase III clinical trial of the investigational therapy Multikine (Leukocyte Interleukin, Injection) to 4 additional European countries - Spain, Czech Republic, Slovakia and Croatia.

27 Dec 2011

People in Northern Ireland less likely to develop cancers

People in Northern Ireland have a lower risk of developing some cancers than those living in the Republic of Ireland, according to the All-Ireland Cancer Atlas - a collaborative publication by the Northern Ireland Cancer Registry at Queen's University Belfast and the National Cancer Registry in Cork.

12 Dec 2011

Aethlon receives approval to begin Hemopurifier study at Sarcoma Oncology Center

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that a cancer research study to test the ex vivo effectiveness of the Aethlon Hemopurifier to capture tumor-secreted exosomes from the blood of advanced-stage cancer patients has received institutional review board approval to begin studies at the Sarcoma Oncology Center, based in Santa Monica, California.

7 Dec 2011

IsoRay initiates shipment of GliaSite radiation therapy system

IsoRay, Inc. announced today it has shipped its first GliaSite radiation therapy system. The Company initiated sales after receiving final approval this week from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system.

28 Nov 2011

Einstein, Montefiore experts available to discuss effects of radiation dose and exposure

Experts from Montefiore Medical Center and Albert Einstein College of Medicine of Yeshiva University are available for interviews on topics ranging from effects of radiation dose and exposure to MRI imaging to detect brain damage in soccer players due to "heading" and cancer post-treatment imaging during the annual Radiological Society of North America Scientific Assembly.

24 Nov 2011

IsoRay receives Washington State approval for GliaSite system to treat brain cancer

IsoRay, Inc. announced today it has received final approval from the State of Washington Department of Health to manufacture its GliaSite radiation therapy system, a balloon catheter device used in the treatment of brain cancer. In conjunction with the previously announced FDA clearance, the Washington State approval represents IsoRay's final regulatory hurdle to commence the sale of its GliaSite brain cancer treatment in the United States.

22 Nov 2011

SAFC commences process validation activities for Oncolytics' REOLYSIN

Oncolytics Biotech Inc. today announced that SAFC, a Division of Sigma-Aldrich Corporation, has commenced validation activities designed to demonstrate the manufacturing process for the commercial production of REOLYSIN, Oncolytics' proprietary formulation of reovirus, is robust and reproducible.

21 Nov 2011

Community-based cancer screening may increase awareness of smoking, reduce at-risk behaviors

Large, population specific community-based screening may increase awareness of the dangers of smoking and reduce at-risk behaviors, according to a new study in the November 2011 issue of Otolaryngology-Head and Neck Surgery.

16 Nov 2011

Positive results from Oncolytics REOLYSIN combination Phase 2 clinical trial for head and neck cancers

Oncolytics Biotech Inc. today announced that positive results from a Phase 2 clinical trial (REO 015) using intravenous administration of REOLYSIN in combination with paclitaxel and carboplatin in patients with advanced head and neck cancers will be presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

14 Nov 2011

First large scale trial of acupuncture for prevention of xerostomia

When given alongside radiation therapy for head and neck cancer, acupuncture has shown for the first time to reduce the debilitating side effect of xerostomia, according to new research from The University of Texas MD Anderson Cancer Center and Fudan University Shanghai Cancer Center.

11 Nov 2011

Idera third quarter net loss increases to $5.5 million

Idera Pharmaceuticals, Inc. today reported financial results for the third quarter ended September 30, 2011. Idera is a biotechnology company engaged in the discovery and development of DNA- and RNA-based drug candidates targeted to Toll-like receptors (TLRs).

9 Nov 2011

Bristol-Myers Squibb receives FDA approval for Erbitux to treat head and neck cancer

The U.S. Food and Drug Administration today approved Erbitux (cetuximab) for use with chemotherapy to treat patients with late-stage (metastatic) head and neck cancer.

8 Nov 2011

PSTC, FNIH Biomarkers Consortium launch clinical study to improve detection of kidney injury

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium announced today the launch of a two-year clinical study aiming to advance the acceptance of new biomarkers designed to detect drug-induced kidney injury in clinical trials.

2 Nov 2011